ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

The topoisomerase-I inhibitor topotecan [‘Hycamtin’; SmithKline Beecham] is at least as effective as paclitaxel in the treatment of recurrent ovarian cancer, according to the final results of a phase III study presented at the 21st Congress of the European Society for Medical Oncology (ESMO) [Vienna, Austria; November 1996]. These results provide physicians with confidence regarding the use of topotecan as an effective option for treating ovarian cancer in patients who receive paclitaxel in combination with a platinum compound as first-line therapy, said Dr Win W ten Bokkel Huinink from the Netherlands Cancer Institute, Amsterdam, The Netherlands.

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

The results of trials involving 3- or 4-drug combinations as therapy for patients with HIV infection have caused considerable excitement this year. Treatment with such combinations has been shown to significantly improve patient outcome. However, combination drug therapy is expensive and involves complicated dosing regimens. Thus, it is not a practical answer to the problem of HIV infection in developing countries. Here, therapeutic and prophylactic vaccines are likely to be a more realistic approach due to their lower cost and simpler administration regimens. The latest progress in HIV vaccine development was discussed at the 3rd International Congress on Drug Therapy in HIV Infection [Birmingham, UK; November, 1996].

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS